Raymond James & Associates’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Raymond James & Associates’s Portfolio DOVA Stock Details DOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-11,974	Closed	-$169K	–	3772
2019 Q2	$169K	Sell	11,974 -2,879	-19%	-$27.4K	﹤0.01%	3318
2019 Q1	$132K	Sell	14,853 -7,236	-33%	-$58.7K	﹤0.01%	3337
2018 Q4	$167K	Sell	22,089 -24,050	-52%	-$387K	﹤0.01%	3202
2018 Q3	$968K	Sell	46,139 -2,834	-6%	-$67.5K	﹤0.01%	2282
2018 Q2	$1.47M	Buy	+48,973	New	+$1.33M	﹤0.01%	1967

Other funds holding DOVA

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James & Associates's DOVA Position: Q3 2019 in Review

Raymond James & Associates sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q3 2019, closing a stake of 11,974 shares — an estimated $169K sold.

Raymond James & Associates first reported a position in DOVA in Q2 2018 and held it in 5 quarters. The position peaked at $1.47M in Q2 2018. 72 funds tracked by Wall St. Rank hold DOVA as of Q3 2019.

Raymond James & Associates reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Raymond James & Associates sold 11,974 Dova Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $169K.
Raymond James & Associates first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 5 quarters.
Raymond James & Associates's Dova Pharmaceuticals, Inc. Common Stock position peaked at $1.47M in Q2 2018.
72 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Raymond James & Associates's 13F filing for Q3 2019, filed 7 Nov 2019.